BioNotebook: Five VC deals, three public financings, and a round of layoffs
This article was originally published in Scrip
Syros raises $53m Series B; Aileron gets $33m more for Series E; Imago closes $26.5m Series A; $20m equity investment for Xcovery; Affinivax launches with $4m; Synergy sells convertible notes; Regulus, Vanda price stock offerings; and Impax cuts 49 jobs.
You may also be interested in...
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.
Athenex and Immuron launched IPOs in the US, but June has otherwise been a pretty quiet month for new biopharma financings – so far. The largest VC round so far this month is Checkmate's $27m Series B and the biggest public offering was conducted by CTI BioPharma, raising $45m.
Private Company Edition: Perceptive/Xontogeny, Abingworth, Kizoo and Droia closed venture capital funds. New biopharma VC financings also include a $105m series C round for Elpiscience and $92m for newly launched Interline.